Exchange: NASDAQ·Updated 07:37 PM EDT
IMMX logo

IMMXImmix Biopharma Inc

$9.57
$0.77
(8.75%)
Today
Closed $9.57
$0.17
(1.78%)
After Hours
Mkt Cap$626.47M
Vol2.48M
News
all
press releases
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
More News
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.read more...
Benzinga
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
What's Going On With Immix Biopharma Stock Thursday?
Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028. Read the details.read more...
Benzinga
The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms
Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN
24-7 Market News
Immix Biopharma (NASDAQ:IMMX) Trading Down 4.6% - Time to Sell?
Immix Biopharma (NASDAQ:IMMX) Shares Down 4.6% - Time to Sell...
MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 12% Higher - Should You Buy?
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 12% - Still a Buy...
MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages
Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat reports. One...
MarketBeat
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says
Mizuho raised their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Monday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.